Eras­ing can­cer, re­viv­ing on­colyt­ic virus, treat­ing a rare neu­ro­mus­cu­lar con­di­tion: Here's what you need to know about the 5 new biotechs fil­ing for IPOs

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

Last week was a busy one for biotech IPOs, with five more com­pa­nies fil­ing to go pub­lic just be­fore the start of the week­end, in­clud­ing a com­pa­ny led by Glax­o­SmithK­line vet Paul Pe­ter Tak that’s been work­ing on on­colyt­ic virus­es for decades, and a qui­et San Diego-based up­start that’s jump­ing in­to the spot­light with 11 pro­grams com­ing down the pipeline. Each of them pen­ciled in a $100 mil­lion dol­lar raise — but if trends con­tin­ue, they could go on to raise much, much more.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.